Search results
Added:
3 years ago
In late December 2019, an outbreak of an unknown disease called a pneumonia of uncertain cause occurred in Wuhan, Hubei Province, China.1 Over the next few days, several independent laboratories identified the causative agent as a novel coronavirus.2–4 The WHO has temporarily named this virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the related infectious disease…
View more
Added:
3 years ago
The AHA COVID-19 Cardiovascular Disease (CVD) Registry captures data on adult patients hospitalized with COVID-19 in over more than 150 hospitals across the US.
Radcliffe meets with Dr James de Lemos (UT Southwestern Medical Center, TX, US), co-chair of the registry steering committee, to discuss the important role this registry plays in tackling the pandemic and understanding the complexities of…
View more
Added:
1 year ago
ESC Congress 22 — Prof Renato Lopes (Duke University Medical Center, US) talks about the data from the APOLLO trial (NCT04746339).
This randomized, double-blinded trial compared a DOAC, Apixaban 2.5 MG twice daily with placebo for 30 days. The trial assessed this intervention in outpatients with symptomatic SARS-CoV2 infection and risk factors for thrombosis. The primary outcome measure focused…
View more
Added:
1 year ago
ESC Congress 22 — Dr David Berg (Brigham and Women's Hospital, US) shares key results from the TIMI Study Group's COVID-PACT trial (NCT04409834).
This multicenter, randomized-controlled trial assessed efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events. The study…
View more
Added:
1 year ago
ESC Congress 22 — Dr Sanjit Jolly (Population Health Research Institute, CA) talk about the Anti-Coronavirus Therapies (ACT) trials (NCT04324463).
The data is from two parallel trials assessing the effects of interventions in inpatients and outpatients with COVID-19.
The ACT trials are testing whether anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin in…
View more
Added:
1 year ago
AHA 22 - CardioNerds Fellow, Dr Kahtan Fadah(Texas Tech University, US) is joined by PREVENT-HD PI, Dr Gregory Piazza (Brigham and Women's Hospital, US) to discuss the findings revealed at AHA 2022.
PREVENT-HD was designed to evaluate the safety and efficacy of rivaroxaban in reducing the risk of major venous and arterial thrombotic events in patients with COVID-19. Over 1200 patients were…
View more
Added:
2 years ago
What could institutions do to address the issues highlighted by data globally?
In the ACC 21 edition of the Masterclass series, Dr Laxmi Mehta (The Ohio State University, Columbus, OH, US) and Dr Garima Sharma (Johns Hopkins School of Medicine, Baltimore, MD, US) sat down with host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) to discuss two important publications both focusing…
View more
Added:
2 years ago
Added:
2 years ago
Andrew J Sauer
Research Area(s) / Expertise:
Job title: Cardiologist
Author
